Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Brentuximab Vedotin and Bevacizumab in Men With Refractory CD-30 Positive Germ Cell Tumors

NCT02988843 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.

NCT NCT02988843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02988843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Brentuximab Vedotin and Bevacizumab in Men With Refractory CD-30 Positive Germ Cell Tumors
Lead sponsor
Masonic Cancer Center, University of Minnesota
Phase
Phase 2
Overall status
Terminated
Start date
March 29, 2017
Completion date
December 15, 2019
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

germ cell tumor